

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for and loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

RepublicHealthcare

Republic Healthcare Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 8357)

**(1) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS;
(2) CHANGES IN COMPOSITION OF BOARD COMMITTEES;
(3) RESIGNATION OF EXECUTIVE DIRECTOR; AND
(4) CHANGE OF COMPLIANCE OFFICER AND AUTHORISED REPRESENTATIVE**

The Board hereby announces the following changes all with effect from 30 September 2020:

1. Mr. Low has been appointed as an independent non-executive Director of the Company as well as the chairman of the Audit Committee, and a member of each of the Remuneration Committee and the Nomination Committee;
2. Mr. Leung has tendered his resignation as an independent non-executive Director of the Company, and ceased to be the chairman of the Audit Committee, a member of each of the Remuneration Committee and the Nomination Committee;
3. Mr. Toh has tendered his resignation as an executive Director and Chief Financial Officer and ceased to be the Authorised Representative and the Compliance Officer of the Company; and
4. the Authorised Representative and the Compliance Officer of the Company have been changed to Dr. Tan Cher Sen Alan.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHAIRMAN OF THE AUDIT COMMITTEE AND MEMBER OF THE REMUNERATION COMMITTEE AND THE NOMINATION COMMITTEE

The board (the “**Board**”) of directors (the “**Directors**”, each a “**Director**”) of Republic Healthcare Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mr. Low Wee Siong (“**Mr. Low**”) has been appointed as independent non-executive Director of the Company as well as the chairman of the Company’s audit committee (the “**Audit Committee**”) and a member of each of the Company’s nomination committee (the “**Nomination Committee**”) and remuneration committee (the “**Remuneration Committee**”) with effect from 30 September 2020.

The biography of Mr. Low is set out as follows:

Mr. Low, aged 43, Mr. Low has more than a decade of experience in capital markets and corporate finance. Mr. Low is currently in legal practice as a director of Wong Tan & Molly Lim LLC. He was previously in legal practice at Stamford Law Corporation (now known as Morgan Lewis Stamford LLC) and Allen & Gledhill. He was also an investment banker at RHB Bank (Singapore) and at HL Bank Singapore.

Mr. Low has been named as a recommended lawyer for capital markets in Singapore by The Legal 500 Asia-Pacific 2018 and 2020 Editions and amongst the most influential lawyers aged 40 and under in Singapore in 2016 by the Singapore Business Review. Mr. Low is also currently an independent director of Beng Kuang Marine Limited and Propnex Limited, the shares of both of which are listed on the main board of the Singapore Exchange Securities Trading Limited.

Mr. Low holds degrees in accountancy and law from Nanyang Technological University and National University of Singapore respectively. Mr. Low is admitted as an Advocate and Solicitor of the Supreme Court of Singapore, as a solicitor on the Roll of Solicitors in England and Wales and as a Chartered Accountant of Singapore.

Mr. Low has entered into a service agreement with the Company as an independent non-executive Director for a fixed term of one year. Mr. Low is subject to retirement by rotation and re-election at the general meeting of the Company in accordance with the articles of association of the Company. Mr. Low is entitled to a director's fee of SGD 24,000 per annum, which has been determined by the Board upon the recommendation of its remuneration committee by reference to his qualifications, experience, duties and responsibilities within the Group and the prevailing market conditions.

Mr. Low has confirmed that he meets the independence requirement as set out in Rule 5.09 of the Rules Governing the Listing of Securities on the GEM of the Stock Exchange (the "**GEM Listing Rules**").

Save as disclosed above, as at the date of this announcement, Mr. Low does not hold any directorship in any listed public companies in the past three years and does not have relationship with any Directors, senior management or substantial or controlling shareholders of the Company nor any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations which is required to be disclosed under Part XV of the SFO, Chapter 571 of the Laws of Hong Kong and there is no information relating to the appointment of Mr. Low as an independent non-executive Director that is required to be disclosed pursuant to Rules 17.50(2)(h) to (v) of the GEM Listing Rules nor any matters that need to be brought to the attention of the shareholders of the Company (the "**Shareholders**") and the Stock Exchange.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CESSATION AS THE CHAIRMAN OF THE AUDIT COMMITTEE AND MEMBER OF THE REMUNERATION COMMITTEE AND THE NOMINATION COMMITTEE

The Board announces that Mr. Leung Ho San Jason (“**Mr. Leung**”) has tendered his resignation as an independent non-executive Director of the Company, and ceased to be the chairman of the Audit Committee, a member of each of the Remuneration Committee and the Nomination Committee with effect from 30 September 2020 in order to devote to his other business development.

Mr. Leung has confirmed that (i) he does not have any disagreement with the Board; (ii) there are no matters that need to be brought to the attention of the Stock Exchange and the Shareholders in respect of his resignation; and (iii) he has no claims against the Company in respect of fees nor compensation for loss of office or otherwise as an independent non-executive Director.

RESIGNATION OF EXECUTIVE DIRECTOR

The Board announces that Mr. Toh Han Boon (“**Mr. Toh**”) has tendered his resignation as an executive Director and chief financial officer of the Company (the “**Chief Financial Officer**”) with effect from 30 September 2020 in pursuit of his own career development.

Upon Mr. Toh’s resignation, Mr. Toh also ceased to act as (i) an authorised representative of the Company (the “**Authorised Representative**”), and (ii) the compliance officer of the Company (the “**Compliance Officer**”) under Rule 5.24 and 5.19 of the GEM Listing Rules respectively.

Mr. Toh has confirmed that (i) he does not have any disagreement with the Board; (ii) there are no matters that need to be brought to the attention of the Stock Exchange and the Shareholders in respect of his resignation; and (iii) he has no claims against the Company in respect of fees nor compensation for loss of office or otherwise as an executive Director and the Chief Financial Officer.

CHANGE OF AUTHORISED REPRESENTATIVE AND COMPLIANCE OFFICER

The Board further announces that following Mr. Toh’s resignation, the Authorised Representative and the Compliance Officer of the Company have been changed from Mr. Toh to Dr. Tan Cher Sen Alan, the chairman and the executive Director of the Company, with effect from 30 September 2020.

The Board would like to take this opportunity to warmly welcome Mr. Low for joining the Board and express its gratitude to Mr. Leung and Mr. Toh for their valuable contribution to the Company during their tenures of office.

By Order of the Board
Republic Healthcare Limited
TAN Cher Sen Alan
Chairman and Executive Director

Singapore, 30 September 2020

As at the date of this announcement, the executive Director is Dr. Tan Cher Sen Alan (Chairman); and the independent non-executive Directors are Mr. Low Wee Siong, Mr. Soh Sai Kiang and Mr. Kevin John Chia.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquires, confirm that to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkgem.com for at least 7 days from the date of its publication. This announcement will also be published on the website of the Company at republichealthcare.asia.